Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.53 |
| ▸ | PPARG | P37231 | 10/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860189 | 1.00 | PPARA (0.53) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL6692318 | 0.87 | PPARA (0.53) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL8582258 | 0.87 | MAPT (0.44) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL13640190 | 0.87 | PPARA (0.53) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL5921691 | 0.87 | PPARA (0.53) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL18954453 | 0.86 | PPARA (0.55) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL23927278 | 0.85 | PPARA (0.64) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2541324 | 0.85 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL432222 | 0.85 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL1618767 | 0.85 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0052870-A1 | Amino acid derivatives and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-02 | — | — | EP | claimed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| EP-1037668-A1 | TRANSFECTION PARTICLES | Boehringer Ingelheim International GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| EP-0945138-A1 | Transfection particles | Université Louis Pasteur de Strasbourg (FR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999029349-A1 | TRANSFECTION PARTICLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0052870-A1 | Amino acid derivatives and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | PPARA 1169/4885PPARG 1170/4885PPARD 1173/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | PPARA 871/4885PPARG 880/4885PPARD 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.